ZVRA Quote, Financials, Valuation and Earnings

Geron has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -50.09%. Zevra Therapeutics's return on equity of -198.46% beat Geron's return on equity of -46.58%.

Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 136.28%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 127.62%. Given that Zevra Therapeutics has higher upside potential than Geron, analysts believe Zevra Therapeutics is more attractive than Geron.

Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Geron has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.798%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are smaller than Geron quarterly revenues of $39.6M. Zevra Therapeutics's net income of -$3.1M is higher than Geron's net income of -$19.8M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.17x versus 9.22x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Moleculin Biotech has a net margin of -15.19% compared to Zevra Therapeutics's net margin of --. Zevra Therapeutics's return on equity of -198.46% beat Moleculin Biotech's return on equity of --.

Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 136.28%. On the other hand Moleculin Biotech has an analysts' consensus of $9.33 which suggests that it could grow by 1293.03%. Given that Moleculin Biotech has higher upside potential than Zevra Therapeutics, analysts believe Moleculin Biotech is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.562, suggesting its more volatile than the S&P 500 by 56.242%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Moleculin Biotech quarterly revenues of --. Zevra Therapeutics's net income of -$3.1M is higher than Moleculin Biotech's net income of -$6.4M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.17x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -311.07%. Zevra Therapeutics's return on equity of -198.46% beat Macrogenics's return on equity of -58.23%.

Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 136.28%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 156.1%. Given that Macrogenics has higher upside potential than Zevra Therapeutics, analysts believe Macrogenics is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.652, suggesting its more volatile than the S&P 500 by 65.244%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Macrogenics quarterly revenues of $13.2M. Zevra Therapeutics's net income of -$3.1M is higher than Macrogenics's net income of -$41M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.17x versus 0.68x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -479.24%. Zevra Therapeutics's return on equity of -198.46% beat Voyager Therapeutics's return on equity of -26.82%.

Zevra Therapeutics has a consensus price target of $21.71, signalling upside risk potential of 136.28%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.00 which suggests that it could grow by 370.98%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 2.011, which suggesting that the stock is 101.078% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.97%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Voyager Therapeutics quarterly revenues of $6.5M. Zevra Therapeutics's net income of -$3.1M is higher than Voyager Therapeutics's net income of -$31M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 11.17x versus 2.90x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.